CONCLUSIONS: CD44v9 could be a strong prognostic indicator in invasive BC as well as UTUC. Information of CD44v9 positivity might be useful for the appropriate selection of adjuvant systemic therapy in patients with pT2-4N0M0 UC who undergo surgical treatment.
INTRODUCTION AND OBJECTIVES: Urothelial cell carcinoma (UCC) is a common malignancy of urinary tract associated with gene effect and environmental factors. The receptor for advanced glycosylation endproducts (RAGE) is a transmembrane protein of the immunoglobulin superfamily which is well studied and specificity for multiple ligands that plays vital role in several pathophysiologic processes, including diabetes, Alzheimer disease, renal disease, cardiovascular disease, and cancer. The study aimed to explore the impact of RAGE gene polymorphisms on the clinicopathological status and survival of patients with UCC.
METHODS: A total of 1,023 participants, including 431 patients with UCC and 592 healthy people as control group, were recruited for this study. Four polymorphisms of the RAGE genedincluding -374T>A (rs1800624), -429T>C (rs1800625), 1704G>T (rs184003), Gly82Ser (rs2070600) were examed by a real-time PCR with the TaqMan assay.
RESULTS: we found that individuals carrying at least one C allele at RAGE rs1800625 had a higher risk of developing UCC than those with wild-type allele (AOR [1.898, CONCLUSIONS: This is the first reported correlation between RAGE polymorphisms and UCC risk. Individuals carry at least one C allele of rs1800625 of the RAGE associated with higher risk of UCC, especially in age&65, female and without tobacco consumptom. TT polymorphism of rs184003 associated with worse disease specific survival and overall survival in age&65.
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MP63-10 FAM81A GERMLINE COPY NUMBER POLYMORPHISM MAY PREDICT THE EFFICACY OF BCG THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER
Yoshiaki Yamamoto*, Masahiro Samoto, Junichi Mori, Kosuke Shimizu, Ryo Inoue, Seiji Yano, Hiroaki Matsumoto, Hideyasu Matsuyama, Ube, Japan INTRODUCTION AND OBJECTIVES: Bacillus Calmette-Guerin (BCG) intravesical instillation is the most effective immunotherapy for non-muscle-invasive bladder cancer (NMIBC), however there are few reliable markers to elucidate the efficacy of BCG therapy. Germline copy number polymorphisms (CNPs) are expected to affect various diseases including human malignancies, but the significance of CNPs in NMIBC treated with BCG therapy remains unclear. FAM81A located on 15q22.2 was reported as one of tumor-associated ETS shared target genes in prostate cancer. PCSK6 located on 15q26.3 was reported to regulate proliferation and tumor progression in breast and prostate cancer. The purpose of this study is to determine the prognostic value of CNPs for NMIBC treated with BCG therapy. To our knowledge, this is the first report to confirm CNPs as a potential biomarker for assessing the efficacy of immunotherapy.
METHODS: Array comparative genomic hybridization (CGH) was performed to search for candidate whole genome-wide CNPs related to NMIBC susceptibility. Next, quantitative real-time polymerase chain reaction was carried out to evaluate the effect of BCG therapy in 57 NMIBC (21 pTa, 36 pT1, and 46 concurrent CIS) patients treated with BCG intravesical instillation. Tumor recurrence and disease progression were detected in 36 and 16 patients, respectively with a median follow-up period of 85.9 months (range, 17.4-254.4 months).
RESULTS: Eleven CNPs were associated with NMIBC risk in array CGH. FAM81A and PCSK6 copy number according to those CNPs examined showed significant relationship with disease progression in NMIBC treated with BCG. The means of the relative copy numbers of patients with CNP and those without it were 1.58 and 2.10
